$INSM

INSMED Inc

Insmed is a global biopharmaceutical company that develops and commercializes therapies for people with serious diseases. Its commercial products and pipeline are organized across Respiratory, Immunology & Inflammation, and Neuro & Other Rare. In Respiratory, its marketed products are ARIKAYCE, an inhaled amikacin treatment for certain MAC lung infections, and BRINSUPRI, an oral once-daily treatment for non-cystic fibrosis bronchiectasis. Its clinical-stage programs include TPIP and INS1148. The Immunology & Inflammation pipeline includes brensocatib for hidradenitis suppurativa, while Neuro & Other Rare includes gene therapy candidates INS1201 for Duchenne muscular dystrophy and INS1202 for amyotrophic lateral sclerosis. Insmed also conducts preclinical research in areas including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. It makes money through commercializing its products and also evaluates in-licensing and acquisition opportunities for products, candidates, and technologies. Insmed is headquartered in Bridgewater, New Jersey.

1
1
0

No SEC Form 4 filings for $INSM in the last 30 days.

See all $INSM insider activity →
Med

Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead

Insmed (NASDAQ:INSM) expects its drug BRINSUPRI to reach $7 billion in peak sales and anticipates becoming cash-flow positive next year. The company plans a U.S. direct-to-consumer ad campaign for BRINSUPRI and sees potential in treating bronchiectasis in asthma/COPD patients. Insmed also aims to expand ARIKAYCE's market and has multiple pipeline drugs in development, forecasting 20%+ annual revenue growth over the next decade.

Stanley Druckenmiller’s Next 13F Likely Lands Monday. 3 Positions to Watch

Stanley Druckenmiller's Duquesne Family Office must file its Q3 13F by Monday, revealing holdings as of Sept. 30. Top positions in Q2 included Natera, Taiwan Semiconductor, and Insmed, with Natera being the largest at 19.9% of the portfolio. Analysts' average price targets for these stocks are 28% to 61% above current prices. Taiwan Semiconductor's sales have been record-high despite a stock price decline.

INSM sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning INSM (INSMED Inc). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent INSM coverage spans financial news and earnings.

What's driving INSM

AlphAI scores every news story that mentions INSM with an AI model for sentiment and relevance, and aggregates insider trades from INSMED Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $INSM

Score

Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead

Insmed (NASDAQ:INSM) expects its drug BRINSUPRI to reach $7 billion in peak sales and anticipates becoming cash-flow positive next year. The company plans a U.S. direct-to-consumer ad campaign for BRINSUPRI and sees potential in treating bronchiectasis in asthma/COPD patients. Insmed also aims to expand ARIKAYCE's market and has multiple pipeline drugs in development, forecasting 20%+ annual revenue growth over the next decade.

Stanley Druckenmiller’s Next 13F Likely Lands Monday. 3 Positions to Watch

Stanley Druckenmiller's Duquesne Family Office must file its Q3 13F by Monday, revealing holdings as of Sept. 30. Top positions in Q2 included Natera, Taiwan Semiconductor, and Insmed, with Natera being the largest at 19.9% of the portfolio. Analysts' average price targets for these stocks are 28% to 61% above current prices. Taiwan Semiconductor's sales have been record-high despite a stock price decline.

H.C. Wainwright initiates Insmed stock coverage with buy rating

H.C. Wainwright initiated coverage on Insmed (NASDAQ:INSM) with a buy rating and $220 price target, citing its transition into a multi-asset respiratory business and $14B peak sales guidance. Insmed reported Q3 2026 revenue of $524.4M, beating estimates, but posted adjusted losses of -$0.46 per share. Analysts adjusted targets but maintained buy ratings, noting strong sales momentum.

$INSMHighAI 9/10

Why is Insmed stock surging today?

Insmed (INSM) stock surged 14.5% in pre-market trading after reporting Q3 2026 revenues of $524.4M, exceeding estimates. BRINSUPRI generated $400.1M, up 29% from the prior quarter. The company raised full-year revenue guidance for BRINSUPRI to $1.35–$1.40B and ARIKAYCE to $460–$470M. Despite a Q3 EPS miss, the stock traded at $111 in pre-market, recovering from recent lows.

$INSMLowAI 8/10

Insmed earnings missed by $0.07, revenue topped estimates

Insmed (INSM) reported Q3 EPS of -$0.46, missing estimates by $0.07, but revenue of $524.42M exceeded expectations. The stock is down 1.64% over 3 months and 50.07% over 12 months. Analysts have revised EPS 12 times positively and 2 times negatively in the last 90 days. InvestingPro rates its financial health as 'fair performance'.

$INSMHighAI 9/10Earnings

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

INSMED Inc (INSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update —Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over t

Related tickers